Search

Your search keyword '"Sho, Takuya"' showing total 361 results
Start Over Author "Sho, Takuya"
361 results on '"Sho, Takuya"'

1. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment

Author

Sho, Takuya, Suda, Goki, Ohara, Masatsugu, Kohya, Risako, Sasaki, Takashi, Yoshida, Sonoe, Hosoda, Shunichi, Ogawa, Koji, Kitagataya, Takashi, Maehara, Osamu, Ohnishi, Shunsuke, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Baba, Masaru, Yamamoto, Yoshiya, Tsukuda, Yoko, Meguro, Takashi, Yamada, Ren, Kobayashi, Tomoe, Takagi, Tomofumi, and Sakamoto, Naoya

Published
2024
Full Text
View/download PDF

2. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

3. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

4. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

5. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

7. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

8. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

9. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

10. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Foti, Silvia, additional, Camera, Silvia, additional, Stefanini, Bernardo, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei-Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2024
Full Text
View/download PDF

11. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Author

Kawagishi, Naoki, Suda, Goki, Sakamori, Ryotaro, Matsui, Takeshi, Onozawa, Masahiro, Yang, Zijian, Yoshida, Sonoe, Ohara, Masatsugu, Kimura, Megumi, Kubo, Akinori, Maehara, Osamu, Fu, Qingjie, Hosoda, Shunichi, Tokuchi, Yoshimasa, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakai, Hajime, Ohnishi, Shunsuke, Baba, Masaru, Takehara, Tetsuo, and Sakamoto, Naoya

Published
2022
Full Text
View/download PDF

13. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

14. Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma

Author

Ohara, Masatsugu, primary, Suda, Goki, additional, Kohya, Risako, additional, Sasaki, Takashi, additional, Yoda, Tomoka, additional, Yoshida, Sonoe, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Hosoda, Shunichi, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Kawagishi, Naoki, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

16. Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals

Author

Tokuchi, Yoshimasa, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Kitagataya, Takashi, Kubo, Akinori, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Ohara, Masatsugu, Yamada, Ren, Suzuki, Kazuharu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, and Sakamoto, Naoya

Published
2021
Full Text
View/download PDF

17. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Author

Kawagishi, Naoki, Suda, Goki, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Tokuchi, Yoshimasa, Kubo, Akinori, Kitagataya, Takashi, Shigesawa, Taku, Suzuki, Kazuharu, Ohara, Masatsugu, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Kudo, Yusuke, Nishida, Mutsumi, and Sakamoto, Naoya

Published
2021
Full Text
View/download PDF

19. Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.

Author

Iavarone, Massimo, Alimenti, Eleonora, Tada, Toshifumi, Shimose, Shigeo, Suda, Goki, Yoo, Changhoon, Soldà, Caterina, Piscaglia, Fabio, Tosetti, Giulia, Marra, Fabio, Vivaldi, Caterina, Conti, Fabio, Schirripa, Marta, Iwamoto, Hideki, Sho, Takuya, Lee, So Heun, Rizzato, Mario Domenico, Tonnini, Matteo, Rimini, Margherita, and Campani, Claudia

Subjects
HEPATOCELLULAR carcinoma, PORTAL vein, ESOPHAGEAL varices, HEMORRHAGE, ODDS ratio, CONFIDENCE intervals
Abstract

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use may be limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. Methods: In this multicenter international retrospective study, cirrhotic patients treated with lenvatinib for aHCC, were enrolled if upper-gastrointestinal endoscopy was available within 6 months before treatment. Primary endpoint was the incidence of EGV bleeding during lenvatinib therapy; secondary endpoints were predictors for EGV bleeding, prevalence, and risk factors for the presence of EGV and high-risk EGV at baseline, as well as impact of EGV bleeding on patients' survival. Results: 535 patients were enrolled in the study (median age: 72 years, 78% male, 63% viral etiology, 89% Child-Pugh A, 16% neoplastic portal vein thrombosis [nPVT], 56% Barcelona Clinic Liver Cancer-C): 234 had EGV (44%), 70 (30%) were at high risk and 59 were on primary prophylaxis. During lenvatinib treatment, 17 patients bled from EGV (3 grade 5), the 12-month cumulative incidence being 3%. The only baseline independent predictor of EGV bleeding was the presence of baseline high-risk EGV (hazard ratio: 6.94, 95% confidence interval [CI]: 2.23–21.57, p = 0.001). In these patients the 12-month risk was 17%. High-risk varices were independently associated with Child-Pugh B score (odds ratio [OR]: 2.12; 95% CI: 1.08–4.17, p = 0.03), nPVT (OR: 2.54; 95% CI: 1.40–4.61, p = 0.002), and platelets <150,000/μL (OR: 2.47; 95% CI: 1.35–4.50, p = 0.003). Conclusion: In hepatocellular carcinoma patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shimose, Shigeo, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Tosetti, Giulia, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Lee, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Casadei-Gardini, Andrea, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

21. Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan

Author

Sasaki, Takashi, primary, Suda, Goki, additional, Ohara, Masatsugu, additional, Hosoda, Shunichi, additional, Kawagishi, Naoki, additional, Kohya, Risako, additional, Yoda, Tomoka, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Yoshida, Sonoe, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Suzuki, Kazuharu, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Komukai, Sho, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

22. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

Author

Suda, Goki, Hasebe, Chitomi, Abe, Masami, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Haga, Hiroaki, Ueno, Yoshiyuki, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Tsukuda, Yoko, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Inoue, Jun, Terasita, Katsumi, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya, and for the NORTE Study Group

Published
2019
Full Text
View/download PDF

23. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

Author

Suda, Goki, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Hasebe, Chitomi, Abe, Masami, Haga, Hiroaki, Ueno, Yoshiyuki, Masakane, Ikuto, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Kawakami, Atsuhiko, Kumagai, Kenichi, Terasita, Katsumi, Ohara, Masatsugu, Kawagishi, Naoki, Umemura, Machiko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, and Sakamoto, Naoya

Published
2019
Full Text
View/download PDF

24. Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma

Author

Kohya, Risako, primary, Suda, Goki, additional, Ohara, Masatsugu, additional, Sasaki, Takashi, additional, Yoda, Tomoka, additional, Sakurai, Naofumi, additional, Yoshida, Sonoe, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Hosoda, Shunichi, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Suzuki, Kazuharu, additional, Kawagishi, Naoki, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

25. Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shigeo, Shimose, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Gardini, Andrea Casadei, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Leo, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Faujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Tosetti, Giulia, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

26. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

Author

Suda, Goki, Furusyo, Norihiro, Toyoda, Hidenori, Kawakami, Yoshiiku, Ikeda, Hiroki, Suzuki, Michihiro, Arataki, Keiko, Mori, Nami, Tsuji, Keiji, Katamura, Yoshio, Takaguchi, Koichi, Ishikawa, Toru, Tsuji, Kunihiko, Shimada, Noritomo, Hiraoka, Atsushi, Yamsaki, Sho, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Kudo, Mineo, Nagasaka, Atsushi, Furuya, Ken, Yamamoto, Yoshiya, Kato, Kanji, Ueno, Yoshiyuki, Iio, Etsuko, Tanaka, Yasuhito, Kurosaki, Masayuki, Kumada, Takashi, Chayama, Kazuaki, and Sakamoto, Naoya

Published
2018
Full Text
View/download PDF

27. Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper‐LDL cholesterolemia without an increase in body weight

Author

Tokuchi, Yoshimasa, primary, Suda, Goki, additional, Kawagishi, Naoki, additional, Ohara, Masatsugu, additional, Kohya, Risako, additional, Sasaki, Takashi, additional, Yoda, Tomoka, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Kubo, Akinori, additional, Yoshida, Sonoe, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Hosoda, Shunichi, additional, Kitagataya, Takashi, additional, Suzuki, Kazuharu, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

28. Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton

Author

Uchinami, Yusuke, primary, Katoh, Norio, additional, Abo, Daisuke, additional, Morita, Ryo, additional, Taguchi, Hiroshi, additional, Fujita, Yoshihiro, additional, Kanehira, Takahiro, additional, Suzuki, Ryusuke, additional, Miyamoto, Naoki, additional, Takao, Seishin, additional, Matsuura, Taeko, additional, Sho, Takuya, additional, Ogawa, Koji, additional, Orimo, Tatsuya, additional, Kakisaka, Tatsuhiko, additional, Kobashi, Keiji, additional, and Aoyama, Hidefumi, additional

Published
2023
Full Text
View/download PDF

29. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa Ramos, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Stefanini, Bernardo, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Burgio, Valentina, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

30. Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

Author

Yang, Zijian, primary, Suda, Goki, additional, Maehara, Osamu, additional, Ohara, Masatsugu, additional, Yoda, Tomoka, additional, Sasaki, Takashi, additional, Kohya, Risako, additional, Yoshida, Sonoe, additional, Hosoda, Shunichi, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Suzuki, Kazuharu, additional, Kawagishi, Naoki, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, Ohnishi, Shunsuke, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

31. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis

Author

Suda, Goki, primary, Baba, Masaru, additional, Yamamoto, Yoshiya, additional, Sho, Takuya, additional, Ogawa, Koji, additional, Kimura, Megumi, additional, Hosoda, Shunichi, additional, Yoshida, Sonoe, additional, Kubo, Akinori, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Yamada, Ren, additional, Ohara, Masatsugu, additional, Kawagishi, Naoki, additional, Natsuizaka, Mitsuteru, additional, Nakai, Masato, additional, Morikawa, Kenichi, additional, Furuya, Ken, additional, Suzuki, Kazuharu, additional, Izumi, Takaaki, additional, Meguro, Takashi, additional, Terashita, Katsumi, additional, Ito, Jun, additional, Kobayashi, Tomoe, additional, Tsunematsu, Izumi, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

32. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

Author

Kawagishi, Naoki, primary, Suda, Goki, additional, Yamamoto, Yoshiya, additional, Baba, Masaru, additional, Furuya, Ken, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Yoshida, Sonoe, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Hosoda, Shunichi, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Ohara, Masatsugu, additional, Suzuki, Kazuharu, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2023
Full Text
View/download PDF

33. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

Author

Suda, Goki, Ogawa, Koji, Yamamoto, Yoshiya, Katagiri, Masaki, Furuya, Ken, Kumagai, Kenichi, Konno, Jun, Kimura, Megumi, Kawagishi, Naoki, Ohara, Masatsugu, Umemura, Machiko, Ito, Jun, Izumi, Takaaki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Tsubota, Akihito, Shimada, Noritomo, Iio, Etsuko, Tanaka, Yasuhito, and Sakamoto, Naoya

Published
2017
Full Text
View/download PDF

34. Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight.

Author

Tokuchi, Yoshimasa, Suda, Goki, Kawagishi, Naoki, Ohara, Masatsugu, Kohya, Risako, Sasaki, Takashi, Yoda, Tomoka, Maehara, Osamu, Ohnishi, Shunsuke, Kubo, Akinori, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Kitagataya, Takashi, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, and Ogawa, Koji

Subjects
FATTY liver, HEPATITIS C virus, HYPERCHOLESTEREMIA, ANTIVIRAL agents, BODY weight
Abstract

Aim: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct‐acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long‐term changes in the prevalence of fatty liver and hyper‐low‐density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs. Methods: This retrospective study included patients with HCV who achieved sustained virologic response after interferon‐free DAA and analyzed the changes in the prevalence of fatty liver diagnosed with controlled attenuation parameter (CAP), hyper‐LDL cholesterolemia, and their relationships at baseline (n = 100) and 24 weeks (SVR24, n = 100), 96 weeks (SVR96, n = 100), and 144 weeks (SVR144, n = 90) after DAA. Results: In 100 participants, the prevalence of fatty liver (19% vs. 32%, p = 0.0349) and hyper‐LDL cholesterolemia (6% vs. 15%, p = 0.0379) significantly increased without changes in body weight at SVR96. Median total cholesterol, low‐density lipoprotein cholesterol (LDL‐C), and small‐dense‐LDL (sdLDL) levels and CAP values were significantly greater at SVR24, SVR96, and SVR144 than at baseline. Baseline CAP values and changes in CAP values were significantly negatively correlated at every observation point: r = −0.5305, p < 0.0001 at SVR24; r = −0.3617, p = 0.0005 at SVR96; and r = −0.4735, p < 0.0001 at SVR144. A similar relationship was observed in cholesterol levels. Unlike at baseline, CAP values were significantly positively correlated with LDL‐C and sdLDL‐C levels at all observation points after DAAs. Conclusions: Direct‐acting antivirals may cause an increased prevalence of fatty liver accompanying hyper‐LDL cholesterolemia without increased body weight. As post‐SVR liver steatosis could cause HCC, careful follow‐up may be required. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Rimassa, Lorenza, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Pressiani, Tiziana, additional, Kawaguchi, Takumi, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Iavarone, Massimo, additional, Di Costanzo, Giovanni, additional, Marra, Fabio, additional, Scartozzi, Mario, additional, Tamburini, Emiliano, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco Giuseppe, additional, Silletta, Marianna, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Cammarota, Antonella, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

36. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

Author

Hosoda, Shunichi, primary, Suda, Goki, additional, Sho, Takuya, additional, Ogawa, Koji, additional, Kimura, Megumi, additional, Yang, Zijian, additional, Yoshida, Sonoe, additional, Kubo, Akinori, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Nakamura, Akihisa, additional, Yamada, Ren, additional, Ohara, Masatsugu, additional, Kawagishi, Naoki, additional, Natsuizaka, Mitsuteru, additional, Nakai, Masato, additional, Morikawa, Kenichi, additional, Furuya, Ken, additional, Baba, Masaru, additional, Yamamoto, Yoshiya, additional, Suzuki, Kazuharu, additional, Izumi, Takaaki, additional, Meguro, Takashi, additional, Terashita, Katsumi, additional, Ito, Jun, additional, Miyagishima, Takuto, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

38. Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas

Author

Uchinami, Yusuke, Katoh, Norio, Abo, Daisuke, Taguchi, Hiroshi, Yasuda, Koichi, Nishioka, Kentaro, Soyama, Takeshi, Morita, Ryo, Miyamoto, Naoki, Suzuki, Ryusuke, Sho, Takuya, Nakai, Masato, Ogawa, Koji, Kakisaka, Tatsuhiko, Orimo, Tatsuya, Kamiyama, Toshiya, Shimizu, Shinichi, and Aoyama, Hidefumi

Subjects
stereotactic body radiotherapy, real-time tumor-tracking radiotherapy, albumin-bilirubin grade, hepatocellular carcinoma
Abstract

Aim To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. Methods From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter = 9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an alpha/beta ratio of 10 (BED10), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. Results With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade >= 2a. In the multivariate analysis, the mALBI grade (=1 vs. >= 2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 >= 100 Gy group than in the BED10 = 100 Gy to the reference point.

Published
2021

39. Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection

Author

Yamada, Ren, primary, Morikawa, Kenichi, additional, Hotta, Kiyohiko, additional, Iwami, Daiki, additional, Tanabe, Tatsu, additional, Murai, Sachiyo, additional, Shinohara, Nobuo, additional, Yoshida, Sonoe, additional, Hosoda, Shunichi, additional, Kubo, Akinori, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Kimura, Megumi, additional, Yamamoto, Koji, additional, Nakai, Masato, additional, Sho, Takuya, additional, Suda, Goki, additional, Natsuizaka, Mitsuteru, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

40. Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Author

Rimini, Margherita, primary, Kang, Wonseok, additional, Burgio, Valentina, additional, Persano, Mara, additional, Aoki, Tamoko, additional, Shimose, Shigeo, additional, Tada, Toshifumi, additional, Kumada, Takashi, additional, Sho, Takuya, additional, Lai, Eleonora, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Tonnini, Matteo, additional, Tamburini, Emiliano, additional, Hiraoka, Atsushi, additional, Takaguchi, Koichi, additional, Nishida, Naoshi, additional, Iwamoto, Hideki, additional, Itobayashi, Ei, additional, Tsuji, Kunihiko, additional, Sakamoto, Naoya, additional, Ishikawa, Toru, additional, Toyoda, Hidenori, additional, Kudo, Masatoshi, additional, Kawaguchi, Takumi, additional, Hatanaka, Takeshi, additional, Nouso, Kazugiro, additional, Suda, Goki, additional, Cabibbo, Giuseppe, additional, Marra, Fabio, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, Pedica, Federica, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei‐Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

41. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

Author

Sho, Takuya, primary, Suda, Goki, additional, Yamamoto, Yoshiya, additional, Furuya, Ken, additional, Baba, Masaru, additional, Ogawa, Koji, additional, Kubo, Akinori, additional, Tokuchi, Yoshimasa, additional, Fu, Qingjie, additional, Yang, Zijian, additional, Kimura, Megumi, additional, Kitagataya, Takashi, additional, Maehara, Osamu, additional, Ohnishi, Shunsuke, additional, Nakamura, Akihisa, additional, Yamada, Ren, additional, Ohara, Masatsugu, additional, Kawagishi, Naoki, additional, Natsuizaka, Mitsuteru, additional, Nakai, Masato, additional, Suzuki, Kazuharu, additional, Izumi, Takaaki, additional, Meguro, Takashi, additional, Terashita, Katsumi, additional, Takagi, Tomofumi, additional, Ito, Jun, additional, Kobayashi, Tomoe, additional, Miyagishima, Takuto, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

42. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma

Author

Nakai, Masato, primary, Morikawa, Kenichi, additional, Hosoda, Shunichi, additional, Yoshida, Sonoe, additional, Kubo, Akinori, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Yamada, Ren, additional, Ohara, Masatsugu, additional, Sho, Takuya, additional, Suda, Goki, additional, Ogawa, Koji, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

43. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients

Author

Nakai, Masato, primary, Suda, Goki, additional, Ogawa, Koji, additional, Yoshida, Sonoe, additional, Hosoda, Shunichi, additional, Kubo, Akinori, additional, Tokuchi, Yoshimasa, additional, Kitagataya, Takashi, additional, Yamada, Ren, additional, Shigesawa, Taku, additional, Ohara, Masatsugu, additional, Sho, Takuya, additional, Morikawa, Kenichi, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

45. Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

Author

Suda, Goki, Ito, Jun, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Okamoto, Munenori, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Yoshida, Junichi, Meguro, Takashi, Ohara, Masatsugu, Kawagishi, Naoki, Kimura, Megumi, Umemura, Machiko, Izumi, Takaaki, Tsukuda, Yoko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, and Sakamoto, Naoya

Published
2018
Full Text
View/download PDF

46. Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma

Author

Maehara, Osamu, Suda, Goki, Natsuizaka, Mitsuteru, Ohnishi, Shunsuke, Komatsu, Yoshito, Sato, Fumiyuki, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Shimazaki, Tomoe, Kimura, Megumi, Asano, Ayaka, Fujimoto, Yoshiyuki, Ohashi, Shinya, Kagawa, Shingo, Kinugasa, Hideaki, Naganuma, Seiji, Whelan, Kelly A, Nakagawa, Hiroshi, Nakagawa, Koji, Takeda, Hiroshi, and Sakamoto, Naoya

Published
2017
Full Text
View/download PDF

47. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment

Author

Suda, Goki, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Kumagai, Kenichi, Kudo, Mineo, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Yoshida, Junichi, Meguro, Takashi, Kimura, Megumi, Ito, Jun, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Tsukuda, Yoko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, and Sakamoto, Naoya

Published
2017
Full Text
View/download PDF

48. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

Author

Suda, Goki, Kudo, Mineo, Nagasaka, Atsushi, Furuya, Ken, Yamamoto, Yoshiya, Kobayashi, Tomoe, Shinada, Keisuke, Tateyama, Miki, Konno, Jun, Tsukuda, Yoko, Yamasaki, Kazushi, Kimura, Megumi, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Terashita, Katsumi, Nakai, Masato, Horimoto, Hiromasa, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, and Sakamoto, Naoya

Published
2016
Full Text
View/download PDF

49. Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia

Author

Takimoto-Sato, Michiko, primary, Miyauchi, Toshinari, additional, Suzuki, Masaru, additional, Ujiie, Hideyuki, additional, Nomura, Toshifumi, additional, Ikari, Tomoo, additional, Nakamura, Tomohiko, additional, Takahashi, Kei, additional, Matsumoto-Sasaki, Machiko, additional, Kimura, Hirokazu, additional, Kimura, Hiroki, additional, Matsui, Yuichiro, additional, Kitagataya, Takashi, additional, Yamada, Ren, additional, Suzuki, Kazuharu, additional, Nakamura, Akihisa, additional, Nakai, Masato, additional, Sho, Takuya, additional, Ogawa, Koji, additional, Sakamoto, Naoya, additional, Yamaguchi, Naoko, additional, Otsuka, Noriyuki, additional, Tomaru, Utano, additional, and Konno, Satoshi, additional

Published
2022
Full Text
View/download PDF

50. Overestimated renal function in patients with liver cirrhosis predicts poor prognosis

Author

Yoshida, Sonoe, primary, Suda, Goki, additional, Ohara, Masatsugu, additional, Kimura, Megumi, additional, Yang, Zijian, additional, Maehara, Osamu, additional, Fu, Qingjie, additional, Hosoda, Shunichi, additional, Akinori, Kubo, additional, Tokuchi, Yoshimasa, additional, Yamada, Ren, additional, Kitagataya, Takashi, additional, Suzuki, Kazuharu, additional, Kawagishi, Naoki, additional, Nakai, Masato, additional, Sho, Takuya, additional, Natsuizaka, Mitsuteru, additional, Morikawa, Kenichi, additional, Ogawa, Koji, additional, Ohnishi, Shunsuke, additional, and Sakamoto, Naoya, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results